Thymidylate synthase expression and prognosis in colorectal cancer: A meta-analysis of colorectal cancer survival data

International Journal of Biological Markers

Volumn 27, Issue 3, 2012, Pages

  Chen, Yao ^a   Yi, Cuihua ^b   Liu, Lian ^b   Li, Bei ^b   Wang, Yawei ^b   Wang, Xiuwen ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Prognosis; Survival; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DATA ANALYSIS; DISEASE FREE SURVIVAL; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE;

EID: 84867559772     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2012.9584     Document Type: Article

References (54)

1. Ciaparrone M, Quirino M, Schinzari G, et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 2006; 70: 366-77.
2. Fariña-Sarasqueta A, Gosens MJ, Moerland E, et al. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Cell Oncol 2010; 33: 1-11.
3. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-36.
4. Donada M, Bonin S, Nardon E, et al. Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-fluorouracil independently of microsatellite instability. J Cancer Res Clin Oncol 2011; 137: 201-10.
5. Hitre E, Budai B, Adleff V, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15: 723-30.
6. Rosati G, Chiacchio R, Reggiardo G, De Sanctis D, Manzione L. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival. Tumour Biol 2004; 25: 258-63.
7. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009; 45: 1890-6.
8. Morgenstern H, Kleinbaum DG, Krupper LL. Measures of disease incidence used in epidemiologic research. Int J Epidemiol 1980; 9: 97-104.
9. Prall F, Ostwald C, Schiffmann L, Barten M. Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? Oncol Rep 2007; 18: 203-9.
10. Sakamoto J, Hamashima H, Suzuki H, et al. Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep 2003; 10: 1081-90.
11. Nanni O, Volpi A, Frassineti GL, et al. Role of biological markers in the clinical outcome of colon cancer. Br J Cancer 2002; 87: 868-75.
12. Cascinu S, Graziano F, Valentini M, et al. Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 2001; 12: 239-44.
13. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008; 19: 915-9.
14. Kamoshida S, Matsuoka H, Ishikawa T, et al. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Jpn J Clin Oncol 2004; 34: 594-601.
15. Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ 2001; 323: 224-8.
16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
17. Zhou LP, Luan H, Dong XH, Jin GJ, Man DL, Shang H. Vascular endothelial growth factor gene polymorphisms and colorectal cancer risk: a meta-analysis. Genet Mol Res 2011; 10: 3674-88.
18. Ren DN, Kim IY, Koh SB, et al. Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. J Surg Oncol 2009; 100: 546-52.
19. Okumura K, Mekata E, Shiomi H, et al. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 2008; 61: 587-94.
20. Popat S, Chen Z, Zhao D, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006; 17: 1810-7.
21. Sinicrope FA, Rego RL, Halling KC, et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 2006; 12: 2738-44.
22. Dotor E, Cuatrecases M, Martínez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24: 1603-11.
23. Ochiai T, Nishimura K, Noguchi H, et al. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 2006; 118: 3084-8.
24. Ohrling K, Edler D, Hallström M, Ragnhammar P, Blomgren H. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol 2005; 23: 5628-34.
25. Aguiar S Jr, Lopes A, Soares FA, et al. Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer. Eur J Surg Oncol 2005; 31: 863-8.
26. Broll R, Busch P, Duchrow M, et al. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis 2005; 20: 94-102.
27. Funahashi K, Koike J, Saito N, et al. Clinical significance of TS and DPD activities in colorectal carcinoma as a predictive factor of UFT sensitivity. Gan To Kagaku Ryoho 2004; 31: 189-93.
28. Tsuji T, Hidaka S, Sawai T, et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 2003; 9: 3700-4.
29. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003; 21: 241-50.
30. Allegra CJ, Parr AL, Wold LE, et al. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol; 20:1735-43.
31. Karlberg M, Ohrling K, Edler D, Hallström M, Ullén H, Ragnhammar P. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res 2010; 30: 645-51.
32. Tarabar D, Knezevic-Usaj S, Petrovic Z, Jovanovic D, Doder R. Prognostic value of thymidylate synthase, epidermal growth factor receptors and vascular endothelial growth factor in patients with stage III colon cancer. Acta Chir lugosl 2006; 53: 143-50.
33. Lassmann S, Hennig M, Rosenberg R, et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 2006; 21: 238-47.
34. Westra JL, Hollema H, Schaapveld M, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005; 16: 1646-53.
35. Katsumata K, Sumi T, Wada T, Katou K, Aoki T. Prognosis and efficacy of postoperative adjuvant chemotherapy in colorectal cancer correlates with nucleic acid metabolizing enzymes. Gan To Kagaku Ryoho 2004; 31: 1357-60.
36. Kornmann M, Schwabe W, Sander S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 4116-24.
37. Sugiyama Y, Kato T, Nakazato H, et al. Retrospective study on thymidylate synthase as a predictor of outcome and sensitivity to adjuvant chemotherapy in patients with curatively resected colorectal cancer. Anticancer Drugs 2002; 13: 931-8.
38. Kornmann M, Link KH, Galuba I, et al. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002; 6: 331-7.
39. Tomiak A, Vincent M, Earle CC, et al. Thymidylate synthase expression in stage II and III colon cancer: a retrospective review. Am J Clin Oncol 2001; 24: 597-602.
40. Matsui T, Omura K, Kawakami K, Morita S, Sakamoto J. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol Rep 2006; 16: 1111-5.
41. Suh KW, Kim JH, Kim YB, Kim J, Jeong S. Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg 2005; 9: 336-42.
42. Fernández-Contreras ME, Jiménez De Ayala B, García De Paredes ML, et al. Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil. Int J Oncol 2004; 25: 877-85.
43. Edler D, Glimelius B, Hallström M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20: 1721-8.
44. Fernández-Contreras ME, Sánchez-Hernández JJ, Guijarro M, et al. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. Oncol Rep 2010; 23: 1393-400.
45. Park CM, Lee WY, Chun HK, et al. Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. J Surg Oncol 2010; 101: 22-7.
46. Kostopoulos I, Karavasilis V, Karina M, et al. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 2009; 9: 339.
47. Gusella M, Frigo AC, Bolzonella C, et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009; 100: 1549-57.
48. Yamada H, Iinuma H, Watanabe T. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep 2008; 19: 729-35.
49. Lurje G, Zhang W, Yang D, et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 2008; 18: 161-8.
50. Jensen SA, Vainer B, Sorensen JB. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 2007; 120: 694-701.
51. Nief N, Le Morvan V, Robert J. Involvement of gene polymorphisms of thymidylate synthase in gene expression, protein activity and anticancer drug cytotoxicity using the NCI-60 panel. Eur J Cancer 2007; 43: 955-62.
52. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
53. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-7.
54. Mandola MV, Stoehlmacher J, Zhang W, et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA level. Pharmacogenetics 2004; 14: 319-27. al